GSK posts Q3 2026 earnings beat, reaffirms guidance amid vaccine weakness
GSK reported third‑quarter 2026 sales of £8.89 billion, up 5% at constant exchange rates, and core earnings per share of 54.6 pence, a 1% increase. Total operating profit fell 16% to £2.13 billion after a £328 million restructuring charge, while core operating profit rose 5% to £3.08 billion. The company reaffirmed its 2026 guidance of 3‑5% turnover growth and 7‑9% core operating‑profit growth at constant exchange rates, and announced a 17 p per share dividend and completion of a £2 billion share‑buyback programme.
Why it matters
Barclays maintained a Sell rating, noting the lower‑half core EPS outlook and higher interest costs, which helped push the share price down 4‑5% on the day (source 13). The earnings beat is offset by a 2% decline in vaccine sales and a 16% drop in statutory profit, raising concerns about near‑term profitability.
Key facts
- 1Q3 2026 sales were £8.89 billion, up 5% at constant exchange rates. globalbankingandfinance.com
- 2Core earnings per share were 54.6 pence, up 1% year‑on‑year. asktraders.com
- 3Total operating profit fell 16% to £2.127 billion. asktraders.com
- 4Core operating profit rose 5% to £3.076 billion. rttnews.com
- 5A £328 million restructuring charge was recorded. asktraders.com
- 6The quarterly dividend was set at 17 p per share. directorstalkinterviews.com
Summary written by AlphAI AI Desk from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.